Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.36 |
| ▸ | NQO2 | P16083 | 10/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16744692 | 0.89 | SRD5A1 (0.41) | ESR1ESR2SRD5A1 | |
| SCHEMBL7220825 | 0.83 | HTR2C (0.44) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL9630429 | 0.82 | MTNR1A (0.56) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL6968070 | 0.81 | PPARD (0.41) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL14143008 | 0.80 | CA2 (0.45) | MTNR1AMTNR1B | |
| SCHEMBL6978852 | 0.80 | CA2 (0.45) | MTNR1AMTNR1B | |
| SCHEMBL7214795 | 0.79 | GRIN2B (0.41) | HTR2A | |
| SCHEMBL6976757 | 0.79 | MTNR1A (0.40) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL3361207 | 0.76 | HTR2A (0.46) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL21954285 | 0.75 | MTNR1A (0.40) | MTNR1AMTNR1BNQO2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946538-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2003-08-06 | — | — | EP | disclosed |
| US-6552044-B2 | Dopamine receptors | H. LUNDBECK A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-0946542-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2002-10-09 | — | — | EP | disclosed |
| US-6436940-B1 | — | — | 2002-08-20 | — | — | US | disclosed |
| US-6436940-B2 | COMBINED EFFECTS OF DOPAMINE D4 RECEPTOR LIGANDS AND SEROTONIN REUPTAKE INHIBITORS; SCHIZOPHRENIA; ANTIDEPRESSANT; ANXIOLYTIC AGENTS; PSYCHOLOGICAL DISORDERS; PANIC, SLEEP AND OBSESSIVE COMPULSIVE DISORDERS; ANTIISCHEMIC AGENTS | H. LUNDBECK A/S (DK) | 2002-08-20 | — | — | US | disclosed |
| US-6352988-B2 | HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION | H. LUNDBECK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-6331544-B1 | TREATING POSITIVE AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA AND OTHER PSYCHOSES | H. LUNDBECK A/S (DK) | 2001-12-18 | — | — | US | disclosed |
| US-20010051625-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-12-13 | — | — | US | disclosed |
| US-20010021777-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-20010020095-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-06 | — | — | US | disclosed |
| US-6262087-B1 | HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. | H. LUNDBECK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| EP-0946542-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| EP-0946538-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028293-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H.LUNDBECK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998028290-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051625-A1 | Indane or dihydroindole derivatives | DRD2, SLC6A3, DRD1 | HTR2C 11/4885HTR2A 26/4885HTR2B 22/4885 |
| US-20010020095-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | HTR2C 9/4885HTR2A 32/4885HTR2B 58/4885 |
| US-20010021777-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | HTR2C 9/4885HTR2A 32/4885HTR2B 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.